T-DXd Granted First-Ever Tissue-Agnostic ADC Approval
Abstract: Trastuzumab deruxtecan became the first antibody–drug conjugate (ADC) to receive tissue-agnostic approval from the FDA, broadening its application to include any advanced solid tumor exhibiting high HER2 expression. This label expansion underscores the versatility of HER2-targeted therapy and charts a new regulatory path for other ADCs to follow.